Ruskovska, Tatjana and Kamcev, Nikola and Kamceva, Gordana and Siljanovski, Nikola (2011) Reproducibility of 3-part differential hematology analyzer medonic ca620: a study after 3 years and 90 000 samples. In: EPMA-World Congress, 15 -18 September 2011, Bonn, Germany.
Text
13167_2011_Article_108.pdf Download (657kB) |
Abstract
BACKGROUND: Three-part differential hematology analyzers, as a common equipment of hematology departments in routine clinical laboratories, are indispensable tool for early diagnostics and monitoring of therapy in different hematological and infectious diseases. Besides regular calibration and quality control according to good laboratory practice, a periodical check of analyzer’s reproducibility is essential for getting the high quality results that will contribute to improve the patients care. According to manufacturer’s data Medonic CA620 hematology analyzer has the best overall reproducibility of all 3-part differential hematology analyzers currently available on Macedonian market.
AIM OF THE STUDY: The aim of our study was to determine the reproducibility of hematology analyzer Medonic CA620 after 3 years of intensive exploitation and 90 000 samples analyzed. We have also compared the obtained data with results from similar study conducted after 9 months of intensive exploitation of the same analyzer and with data given from manufacturer.
MATERIAL AND METHODS: Reproducibility of 3-part differential hematology analyzer Medonic CA620 was assessed by measuring four different fresh samples, each counted 12 times. The reproducibility of five parameters: hemoglobin (HGB), red blood cells (RBC), mean corpuscular volume (MCV), white blood cells (WBC) and platelets (PLT) was expressed as coefficient of variation (CV) of twelve measurements.
RESULTS: For hemoglobin the following results were obtained: 13,4 ± 0,1 g/dL, CV=0,75%; 12,3 ± 0,1 g/dL, CV=0,81%; 10,8 ± 0,1 g/dL, CV=0,93%; 10,0 ± 0,1 g/dL, CV=1,00% (mean CV=0,87%). The results for hemoglobin reproducibility obtained from previous study were 12,9 ± 0,1 g/dL, CV=0,78%, and the manufacturer states for hemoglobin CV= 0,60%.
For RBC the following results were obtained: 5,10 ± 0,06 x 106/μL, CV=1,18%; 4,86 ± 0,05 x 106/μL, CV=1,03%; 4,51 ± 0,05 x 106/μL, CV=1,11%; 3,41 ± 0,02 x 106/μL, CV=0,59% (mean CV=0,98%). The results for RBC reproducibility obtained from previous study were 4,63 ± 0,03 x 106/μL, CV=0,65%, and the manufacturer states for red blood cells CV= 0,85%.
For MCV the following results were obtained: 93,8 ± 0,5 fL, CV=0,53%; 87,0 ± 0,3 fL, CV=0,34%; 86,0 ± 0,2 fL, CV=0,23%; 70,1 ± 0,2 fL, CV=0,29% (mean CV=0,35%). The results for MCV reproducibility obtained from previous study were 78,0 ± 0,2 fL, CV=0,26%, and the manufacturer states for mean corpuscular volume CV= 0,50%.
For WBC the results were the following: 17,2 ± 0,2 x 103/μL, CV=1,2%; 12,3 ± 0,2 x 103/μL, CV=1,6%; 6,7 ± 0,1 x 103/μL, CV=1,5%; 4,6 ± 0,1 x 103/μL, CV=2,2% (mean CV=1,6%). The results for WBC reproducibility obtained from previous study were 4,6 ± 0,1 x 103/μL, CV=2,2%, and the manufacturer states for white blood cells CV= 2,0%.
Finally, for PLT the results were the following: 292 ± 12 x 103/μL, CV=4,1%; 210 ± 7 x 103/μL, CV=3,3%; 188 ± 8 x 103/μL, CV=4,3%; 94 ± 8 x 103/μL, CV=8,5% (mean CV=5,1%). The results for PLT reproducibility obtained from previous study were 233 ± 8 x 103/μL, CV=3,4%, and the manufacturer states for platelets CV= 3,3%.
CONCLUSION: Besides the intensive 3-years exploitation and 90 000 samples analyzed, the 3-part differential hematology analyzer Medonic CA620 still has an excellent reproducibility of results both for normal and pathological samples that is a basis of high quality medical care, including the preventive medicine.
Item Type: | Conference or Workshop Item (Poster) |
---|---|
Subjects: | Medical and Health Sciences > Clinical medicine |
Divisions: | Faculty of Medical Science |
Depositing User: | Tatjana Ruskovska |
Date Deposited: | 24 Nov 2012 12:59 |
Last Modified: | 24 Nov 2012 12:59 |
URI: | https://eprints.ugd.edu.mk/id/eprint/1895 |
Actions (login required)
View Item |